Should you buy Frequency Therapeutics (Freq) stock?

According to 3 analysts, the average rating for FREQ stock is "Hold." The 12-month stock price forecast is $4.0, which is an increase of 912.66% from the latest price. LEXINGTON, Mass.-- (BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023.

What did Frequency Therapeutics do in Q2 2023?

LEXINGTON, Mass., August 10, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs.

Does Frequency Therapeutics have research coverage?

Frequency Therapeutics has received no research coverage in the past 90 days. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function.

What is Frequency Therapeutics' short interest?

What is Frequency Therapeutics' current short interest? Short interest is the volume of Frequency Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 881,700 shares of FREQ short. 2.75% of Frequency Therapeutics' shares are currently sold short.